Clinical Trial Update: Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) [Phase 2]

View source ↗

Summary

Phase 2 safety and pharmacokinetic study of oral MK-8527 QM in participants at low risk for HIV-1 infection; the trial is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• HIV Pre-exposure Prophylaxis

Drugs mentioned

• MK-8527 QM (MK-8527 QM)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV, HIV Pre-exposure Prophylaxis | Phase 2 | Status: COMPLETED | Results posted: 2026-01-07